Table 2 Patient characteristics and exposure to regorafenib treatment
N = 47 | |
|---|---|
Gender, n % | |
Male | 26 (55) |
Female | 21 (45) |
Age (years), median [range] | 81 [63–89] |
ECOG PS, n % | |
0 | 5 (11) |
1 | 25 (56) |
2 | 17 (36) |
Frailty criteria, n % | |
Dependence for daily activities | 8 (17) |
History of comorbidities | 13 (28) |
Geriatric symptoms | 6 (13) |
Dependence + Comorbidities | 8 (17) |
Dependence + Geriatric features | 6 (13) |
Comorbidities + Geriatric Features | 2 (4.3) |
Dependence + Geriatric Features + Comorbidities | 4 (8.5) |
Primary tumor site, n % | |
Colon | 32 (68) |
Rectum | 14 (30) |
Both | 1 (2.1) |
Metastatic at first diagnosis, n % | 30 (64) |
Metastatic sites, n % | |
Liver | 31 (66) |
Lung | 29 (62) |
Peritoneum | 11 (23) |
Bone | 1 (2.1) |
Number of organs involved by M1 disease, n % | |
1 | 17 (36) |
2 | 14 (30) |
3 | 12 (25) |
4 | 2 (4.3) |
5 | 2 (4.3) |
Prior surgery, n % | 31 (66) |
Prior radiation therapy, n % | 6 (13) |
Prior adjuvant chemotherapy, n % | 7 (15) |
Capecitabine alone | 4 (0.8) |
Capecitabine-oxaliplatin | 3 (0.6) |
Exposure to regorafenib | |
Dose intensity (mg/day), median [range] | 91 [58–121] |
Relative dose intensity (mg/day/theoretical total dose), % [range] | 0.76 [0.48–1.01] |